Regulation of Immune Responsiveness In Vivo by Disrupting an Early T-Cell Signaling Event Using a Cell-Permeable Peptide

David M. Guimond¹a, Nicholas R. Cam¹b, Nupura Hirve¹c, Wei Duan²d, John D. Lambris³, Michael Croft², Constantine D. Tsoukas¹*

¹ Department of Biology and Center for Microbial Sciences, San Diego State University, San Diego, California, United States of America
² Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, San Diego, California, United States of America
³ Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America

Abstract

The inducible T cell kinase (ITK) regulates type 2 (Th2) cytokines that provide defense against certain parasitic and bacterial infections and are involved in the pathogenesis of lung inflammation such as allergic asthma. Activation of ITK requires the interaction of its SH3 domain with the poly-proline region of its signaling partner, the SH2 domain containing leukocyte phosphoprotein of 76 kilodaltons (SLP-76). The specific disruption of the ITK-SH3/SLP-76 poly-proline interaction in vitro by a cell-permeable competitive inhibitor peptide (R9-QQP) interferes with the activation of ITK and the transduction of its cellular functions in T lymphocytes. In the present investigation, we assessed the effects of R9-QQP treatment on the induction of an in vivo immune response as represented by lung inflammation in a murine model of allergic asthma. We found that mice treated with R9-QQP and sensitized and challenged with the surrogate allergen ovalbumin (OVA) display significant inhibition of lung inflammation in a peptide-specific manner. Thus, parameters of the allergic response, such as airway hyper-responsiveness, suppression of inflammatory cell infiltration, reduction of bronchial mucus accumulation, and production of relevant cytokines from draining lymph nodes were significantly suppressed. These findings represent the first demonstration of the biological significance of the interaction between ITK and SLP-76 in the induction of an immune response in a whole animal model and specifically underscore the significance of the ITK-SH3 domain interaction with the poly-proline region of SLP-76 in the development of an inflammatory response. Furthermore, the experimental approach of intracellular peptide-mediated inhibition might be applicable to the study of other important intracellular interactions thus providing a paradigm for dissecting signal transduction pathways.

Introduction

The Inducible T cell Kinase (ITK) is a member of the Tec family of tyrosine kinases [1] that is upregulated during type 2 helper T cell (Th2) differentiation [2,3]. Although ITK does not appear to be essential for the development of Th2 cells per se, it is critical for the expression of Th2 cell effector function, as evidenced by defective expression of Th2 cytokines and the transcription factor GATA3 in ITK deficient animals [4]. In view of its role in Th2 cytokine regulation, ITK has also been implicated in the defense against certain parasitic and bacterial infections and in the pathogenesis of lung inflammation such as allergic asthma [5–8].

For its enzymatic activation, ITK requires interaction with the adaptor protein SLP-76 that is induced by the engagement of the T Cell Receptor (TCR) for antigen [9]. In the absence of this interaction, ITK does not become recruited to the appropriate intracellular sites and, consequently, it does not become transphosphorylated and enzymatically activated [9–12]. The association between ITK and SLP-76 is co-operative and involves the interaction between the ITK-SH2 domain and pTyr145 on SLP-76, as well as the interaction between the ITK-SH3 domain and its polyproline ligand on SLP-76 [9,10,13]. In recently published in vitro/ex vivo studies from our laboratory, we disrupted the interaction of ITK and SLP-76 using a novel cell-permeable peptide (denoted R9-QQP) representing the minimal binding motif of the polyproline domain of SLP-76 that interacts with the...
SH3 domain of ITK [12]. Upon TCR-mediated activation of T cells that had been treated with R9-QQP, ITK failed to become recruited to the appropriate intracellular site, its enzymatic activity was reduced, and its ability to transduce the production of TH2 cytokines was compromised [12]. Importantly, these effects were peptide-specific, as separate control peptides displayed no statistically significant effects [12]. Furthermore, the effects of R9-QQP were selective for the ITK/SLP-76 interaction because biochemical interactions between SLP-76 and other SH3 domain-containing proteins known to interact with the poly-proline region of SLP-76 were not affected [12].

The significance of the interaction between ITK and SLP-76 in an in vivo induced immune response has not been previously assessed. In the present investigation, we have investigated the effects of R9-QQP treatment on an immune response mediated by TH2 cytokines, namely lung inflammation as manifested in a murine model of allergic asthma. We found that mice treated with R9-QQP and sensitized and challenged with the surrogate allergen ovalbumin (OVA) display significant inhibition of lung inflammation in a peptide-specific manner. Parameters of the allergic response, such as airway hyper-responsiveness, suppression of inflammatory cell infiltration, reduction of bronchial mucus accumulation and production of relevant cytokines from draining lymph nodes were significantly suppressed.

The data presented here provide the first in vivo evidence for the biological significance of the interaction between ITK and SLP-76 and underscore the importance of the interaction between the SH3 domain of ITK and the poly-proline region of SLP-76 in the generation of an immune response in a whole animal model. The experimental approach using cell-permeable peptides as competitive inhibitors might be also applicable to the study of other important intracellular interactions thus providing a paradigm for dissecting intracellular signal transduction.

Materials and Methods

Ethics Statement

All protocols using mice were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Protocols were approved by the Institutional Animal Care and Use Committees of San Diego State University (A3728-01) and La Jolla Institute for Allergy and Immunology (A3779-01).

Animals

Female BALB/c (experiments presented in Figure 1) or C57BL/6 (all other experiments) mice between the ages of 6-12 weeks were purchased from Jackson Laboratories (Bar Harbor, ME) and were housed in microisolator cages until used for experiments.

Cell-permeable synthetic peptides

RRRRRRRRQQQPPQQPQPMA (R9-QQP), RRRRRRRR-RPQPMPAPQRPQPV (R9-PQM) and RRRRRRRRRQQQA-VAQQRAMA (R9-QQA) peptides were synthesized by GL Biochem, Ltd. (Shanghai, China) using L-enantiomer amino acids as we have previously described [12]. Peptides were purified to >95% purity and their mass was confirmed by matrix-assisted laser desorption mass spectrometry. Peptides were reconstituted in cell culture grade PBS (Mediatech Cellgro/Corning, Inc.; Manassas, VA) for in vivo administration or in cell culture grade water (HyClone/Thermo Fisher Scientific, Inc.; South Logan, UT) for in vitro cultures. R9-PQM is a scrambled sequence of QQP amino acids whereas R9-QQA represents substitution of all

Figure 1. R9-QQP inhibits OVA-inducible Th2 cytokine production in a dose-dependent and peptide-specific manner. Splenocytes, obtained from mice seven days following i.p. immunization with 20 μg OVA + 2 mg alum, were treated with various concentrations of R9-QQP or without peptide and re-stimulated in vitro with 50 μg/mL OVA as indicated. After incubation for 4 days, cell-free tissue culture supernatant samples were assayed for IL-4 (A), IL-5 (C) and IL-13 (E) by ELISA as described in Materials and Methods. Results are those from single titrations for each cytokine and are displayed as the average (± S.D.) of 5-6 replicate experiments utilizing different mice. For each cytokine tested, statistical evaluations were determined by a paired student’s t test comparing peptide-treated cells to vehicle-treated/OVA-pretreated cells. * p < 0.05; **, p < 0.01; #, p > 0.05.

doi:10.1371/journal.pone.0063645.g001

Pro with Ala. Both control peptides behaved similarly and have been used interchangeably in the experiments presented here.

Sensitization to OVA, asthma induction, and peptide treatment

Sensitization to and challenge with the model allergen ovalbumin (OVA, grade V; Sigma; St. Louis, MO; Cat. # A-5503) was performed by intraperitoneal (i.p.) injection of C57BL/6 mice with 20 μg OVA/2 mg alum (Pierce/Thermo Scientific, Inc; Rockford, IL; Cat. # 77161). In order to induce asthma, mice sensitized to OVA were subsequently challenged by intranasal (i.n.) instillation of 10 μg OVA/20 μL PBS into anesthetized mice on days 7, 8, and 9 post sensitization. For peptide treatment, mice sensitized and challenged with OVA as above were treated with R9-QQP or control peptides (R9-PQM or R9-QQA) by i.p. injection of 25 mg peptide per kg of mouse weight (~0.5 mg/mouse) 24 hours and again 30 minutes before OVA sensitization. This was followed by additional i.p. injections of peptides 24 hours before each intranasal challenge with OVA on days 7, 8, and 9 and by i.n. delivery (200 μg in 20 μL PBS) 2 hours before intranasal OVA challenge. According to the above protocol total
peptide delivery was 2.5 mg i.p. and 0.6 mg i.n. per mouse. On
day ten of the protocol mice and collected tissues were used for
assessment of various asthma parameters. The regimen of OVA
sensitization and challenge, and treatment with peptide is outlined
in Figure 2A.

![Figure 2A](https://example.com/figure2a.png)

**Figure 2A.** Regimen of OVA immunization and challenge, and peptide treatment with description of treatment for
each group of mice as detailed in Materials and Methods. Abbreviations
used to represent control groups of mice used for this and subsequent
experiments are defined as follows: NC = negative control, PC = positive
control. (A) Regimen of OVA immunization and challenge with peptide is
outlined in Figure 2A.

**Figure 2B.** Mice treated with R9-QQP display reduced airway
hyperresponsiveness (**AHR**) in response to 12 mg/mL MCh.

![Figure 2B](https://example.com/figure2b.png)

**Figure 2C.** Measurement of airway hyperresponsiveness (**AHR**)
in response to various concentrations of MCh.

**Restimulation of OVA sensitized lymphoid cells in vitro**

Lymphoid cells were isolated from the spleens of mice that had
been sensitized to OVA, as described above, but not treated with
peptide. The spleens were mechanically dissociated and red blood
cells removed by incubation in lysis buffer (0.15 M NH₄Cl, 10 mM KHCO₃,
0.1 mM Na₂EDTA) for 5–10 minute at room temperature. After washing,
the cells were treated with various concentrations of R9-QQP or control
peptides for 30 minutes at 37 °C as previously described [12]. Following peptide treatment,
1×10⁶ cells were cultured in round-bottom 96-well plates
(Sarstedt, Cat. # 83.1837; Numbrecht, Germany) along with
50–100 μg/mL OVA in total volume of 200 μL of RPMI, 10 mM
HEPES, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin and 50 μM 2-mercaptoethanol (2-ME; Sigma) for 4
days at 37 °C in a 5% CO₂ humidified atmosphere. Cell free
supernatants were assessed for the presence of cytokines as
described below. In other experiments, lymphoid cells were
isolated from the peribronchial and mediastinal lung-draining
lymph nodes (DLN) of mice that had been sensitized and
challenged with OVA and treated with the peptide regimen
described above. Cells, 10⁸–10⁹ per microtiter tray well, were
restimulated with OVA, as described above for splenocytes, but
without any in vitro peptide treatment. Culture supernatants were
assessed for cytokine production.

**Assessment of cytokines**

IL-4, IL-5, and IL-13 in culture supernatants from in vitro
ova-restimulated lymphoid cells were quantified by sandwich
ELISA utilizing commercially obtained kits and following the
manufacturer’s recommendations (eBioscience, Inc. San Diego,
CA). All assays had a detection limit of 4 pg/ml and analysis was
performed in duplicate on microtiter well plates (BD Biosciences,
Cat. # 353279) following the manufacturer’s recommendations
(eBioscience, Inc.). Plates were analyzed using the eMax Precision
Microplate Reader and SoftMax Pro v5.0 software (Molecular
Devices, Sunnyvale, CA).

**Measurement of airway hyperresponsiveness (AHR)**

Asthma induction was performed as described above and
invasive airway hyperresponsiveness (**AHR**) of peptide- or control-
treated mice was measured 24 hours after the final challenge with
OVA using the FlexiVent small rodent ventilator system (Scireq,
Inc.; Montreal, QC, Canada). Calibration of the FlexiVent system
was performed prior to acquiring data for each subject according
to the manufacturer’s instructions. First, mice were anesthetized by
i.p. injection of a cocktail containing 80 mg/kg of ketamine
(0.2 mg; Fort Dodge Animal Health; Overland Park, KS) and
8 mg/kg of xylazine (0.2 mg; Lloyd, Inc.; Shenandoah, IA).
Next, the trachea was exposed and a small incision was created at
the location of the cartilage ring; tracheotomy was then performed
by insertion of an 18 gauge cannula (BD Medical, Cat.
# 408208; Franklin Lakes, NJ) that was secured using surgical suture.
Following intratracheal cannulation, the adaptor end of the
cannula was connected to the FlexiVent system and ventilation
was initiated. Once mice were passively breathing, airway
resistance was measured in response to increasing doses of
aerosolized methacholine (Sigma, Cat. # A2251) that were
sequentially delivered to the lungs through the endotracheal
cannula. The maximal airway resistance values for each dose of
methacholine were recorded for each mouse and averaged
(± SEM) for all mice belonging to the same treatment group for each
independent experiment.
Collection of BAL fluid and lung tissue dissociation

Mice were treated following the asthma protocol described above and bronchoalveolar lavage fluid (BALF) was collected 24 hours after the final challenge with OVA. For collection of BALF, tracheotomy was performed as described above and an endotracheal cannula was inserted to a depth of 1 cm beyond the point of incision. One mL of ice-cold PBS was then slowly dispensed to the lungs and aspirated, repeating the process five times. Next, cells were collected by centrifugation and RBCs were lysed using lysis buffer as described above. After performing lavage, lung lobes were excised, rinsed in PBS and minced into 1–2 mm pieces that were digested for 1 hr at 37°C in tissue culture medium containing 3 ng/mL collagenase (Worthington Biochemical Corp., Cat. # LS004186; Lakewood, NJ) and 100 μg/mL DNase I (Sigma, Cat. # DN25). The tissue was then mechanically dissociated and the cell suspension was collected and washed in 0.5% BSA/PBS.

Characterization of cellular infiltrates

BAL cells collected as described above were characterized by preparing cytospin slides using a Shandon Cytospin 2 centrifuge (Thermo Scientific, Inc.; Waltham, MA) and were stained with a modified Wright-Giemsa dye according to the manufacturer’s instructions (Protocol/Fisher HealthCare; Houston, TX; Cat. # 122-911). Alveolar macrophages were identified by light microscopy as large cells with atopic nuclei and cytoplasm staining purple while eosinophils were identified as small cells with bi-lobed nuclei and cytoplasmic granules staining pink.

In addition, cellular infiltrates were quantified for viable cells by erythrosine B (0.15%) staining and counting in a hemocytometer and percentage of subpopulations were assessed by staining with specific fluorochrome-conjugated antibodies (BD Biosciences, San Jose, CA) and analyzed by flow cytometry. Prior to staining, cell surface Fc receptors were blocked by incubation of samples with 0.5 μg of rat anti-mouse CD16/CD32 (Cat. # 553141). Staining for eosinophils and macrophages was performed according to the method described by Stevens et al [14] using a cocktail containing 0.5 μg each of PE-conjugated rat anti-Siglec-F (Cat. # 552126), PerCP-Cy5.5-conjugated rat anti-CD45 (Cat. # 550994) and FITC-conjugated hamster anti-mouse CD11c (Cat. # 574000). Fluorescence of stained cells was acquired using a FACSCanto flow cytometer (BD Biosciences) and FACS analysis was performed using FlowJo software (Tree Star, Inc., Ashland, OR) as follows: first, samples were gated for CD45+ cells that were subsequently analyzed for expression of Siglec-F and CD11c. Eosinophils and macrophages were both positively defined by expression of Siglec-F and were differentially gated based on low versus high expression of CD11c, respectively. Results are expressed as eosinophil and macrophage percentages of CD45+ cells.

Similarly, BAL cells were stained for quantification of T lymphocytes using a cocktail containing 0.5 μg each of PerCP-Cy5.5-conjugated rat anti-CD45 and PE-Cy7-conjugated hamster anti-CD3ε antibodies (Cat. # 552774). Fluorescence of stained cells was acquired using a FACSArray flow cytometer (BD Biosciences) and FACS analysis was performed as follows: first, cells were gated for CD45+ events followed by further defining lymphocytes based on their characteristic scatter profile (FSC/SSC). Lastly, CD45+ cells within this scatter profile were further analyzed for TCR/CD3 expression and T lymphocytes were expressed as a percentage of total CD45+ cells.

For quantification of the absolute number of eosinophils, macrophages and T cells, the percentage of each sub-population as determined by FACS analysis was multiplied by the total number of BAL cells as determined by hemocytometer counts obtained for each mouse.

Histological examination

Separate lung lobes representing each treatment group were fixed in 10% zinc formalin (Protocol/Fisher HealthCare, Cat. # 313-095) and 5 μm paraffin sections were prepared and analyzed for the presence of mucus by staining with periodic acid Schiff (PAS) reagent and counterstaining with hematoxylin. Sample preparation was performed by Pacific Pathology (San Diego, CA). Goblet cell hyperplasia and mucus production were evaluated by assigning a mucus severity score according to the percentage of each bronchiolocyte cross section staining fuchsia as follows: a value of 0 indicates no detectable mucus, a value of 1 indicates≤10% staining positive for mucus, a value of 2 indicates>10% and≤25% staining positive, a value of 3 indicates>25% and≤50% staining positive, a value of 4 indicates>50% and≤75% staining positive and a value of 5 indicates>75% and≥100% staining positive.

Recruitment of inflammatory cells to the lungs was visualized by staining slides prepared as described above with hematoxylin and eosin (H&E). The degree of inflammation was evaluated by assigning a score according to the depth of infiltrating cells surrounding each blood vessel or bronchiole as follows: a value of 0 indicates no infiltrating cells, a value of 1 indicates a single layer of cells, a value of 2 indicates a layer of 2–4 cells, a value of 3 indicates a layer of 5–7 cells and a value of 4 indicates a layer of ≥7 cells.

All of the above evaluations were performed blindly by randomly coding slides prior to visualization by light microscopy using a 40×objective.

Data Analysis

Statistical analysis (student’s t test) and graphical representation of data was performed using Prism software version 5.0 (GraphPad Software; La Jolla, CA). Statistical evaluation of all asthma parameters were determined by a student’s t test comparing each peptide-treated group to the positive control (PC) group; p value < 0.05 was considered statistically significant. For lung histological analyses, raw mucus severity and inflammation scores obtained for each peptide treatment group were normalized to the average PBS/vehicle control treatment, respectively, and values for each group were graphically represented as percentage of control.

Results

Treatment with R9-QQP inhibits OVA-dependent cytokine production by effector T cells

In our previously published in vitro studies in which we found that R9-QQP was able to inhibit ITK activation and compromise Th2 cytokine production, we activated T cells with an anti-TCR stimulatory antibody [12]. Prior to applying the R9-QQP inhibitory peptide in the mouse model of allergic asthma, it was important to demonstrate the ability of R9-QQP to inhibit a T-cell response to an antigen (OVA) that would be later used as a surrogate allergen. To this end, splenocytes isolated from mice that had been sensitized to OVA were treated with R9-QQP and restimulated with OVA in vitro in order to assess cytokine production as part of a T cell-dependent recall response to antigen. Treatment with R9-QQP resulted in a peptide dose-dependent inhibition of three Th2 signature cytokines (IL-4, -5 and -13) that have been implicated in lung inflammation [15] with optimal inhibitory concentration greater than 5 μM (Figures 1A, C, and E). Importantly, when 20 μM of either control peptide (R9-PQM or R9-QQA) was compared to the same amount of R9-
animals that had been previously exposed to OVA internalized (ref. [12] and data not shown). Studies with FITC-labeled peptides have shown that R9-QQP as well as both R9-PQM and R9-QQA control peptides can be internalized (ref. [12] and data not shown).

Inhibition of ITK by R9-QQP reduces lung inflammation-induced airway hyper-responsiveness (AHR)

Lung inflammation, Th2 cytokine production, goblet cell hyperactivity and mucus production are distinctive features of airway allergic conditions such as bronchial asthma [16]. In terms of lung function, these events contribute to the pathophysiological condition of airway hyper-responsiveness [16]. We wished to determine whether inhibition of ITK activation by R9-QQP interferes with this pathophysiological parameter. To this end, we utilized an invasive AHR measurement system (FlexiVent small rodent ventilator system, Scireq Inc.) in which airway resistance is measured in response to increasing doses of aerosolized β-methacholine administered to anesthetized mice by endotracheal delivery. First, we established a methacholine dose response in order to determine an optimal amount of the drug. The data shown in Figure 2B established 12 mg/ml as a dose of methacholine on the plateau of the dose-response curve. Under these conditions, OVA-allergic mice treated with R9-QQP according to the regimen outlined in Figure 2A and detailed in Materials and Methods displayed a significant decrease in AHR (Figure 2, compare R9-QQP and PC bars; p<0.05). Treatment with R9-QQP decreased AHR to levels close to those of mice that were not sensitized (Figure 2C, compare R9-QQP and NC bars; p = 0.2952). Importantly, such a decrease was not seen when mice were treated with the control peptides (Figure 2C).

R9-QQP reduces mucus production and lung inflammation

As mentioned above, the asthmatic response is characterized by mucus accumulation as well as the recruitment of inflammatory infiltrates to the lungs [16]. In the current study, we observed that mucus production was reduced in the bronchi of OVA-allergic mice that were treated with R9-QQP (Figure 3A; compare PC and R9-QQP panels) while mice treated with the control peptide R9-QQA were unaffected (Figure 3A; compare PC and R9-QQA panels). As displayed in Figure 3B, cumulative data from multiple experiments demonstrated that treatment with R9-QQP reduced the mucus severity score by 88% as compared to OVA-allergic mice that were treated with vehicle (PC). In addition, treatment with control peptide R9-QQA did not result in a significant reduction of the mucus severity score for this group of mice.

Goblet cell hyperactivity and mucus accumulation are triggered by the infiltration and accumulation of inflammatory cells that release soluble lipid mediators and sustained production of pathogenic Th2 cytokines [17]. Treatment of OVA-allergic mice with R9-QQP resulted in 71% reduction in the inflammation score as assessed in lung tissue sections that were stained with hematoxylin and eosin (Figure 4A and B). This observation was consistent with the reduction in total cell numbers seen in BAL fluids (Figure 4C and D). Furthermore, microscopic evaluation of inflammatory cells present in BAL fluids indicated that a significant percentage of infiltrating leukocytes were eosinophils (Figure 4C, PC panel).

In order to more precisely characterize as well as quantitate the cellular phenotype and frequency of infiltrating cells, respectively, we analyzed BAL fluid and lung cells by multi-color flow cytometry utilizing a staining approach previously reported by Stevens et al [14]. In these experiments, CD45-positive leukocytes that were stained for Siglec-F and CD11c allowed for the identification of eosinophils as defined by cytoplasms staining fuchsia. (B) Normalized averages (± SEM) of mucus severity scores for the indicated number (n) of mice calculated as described in Materials and Methods; for each mouse, approximately 30 bronchioles were stained and analyzed as in panel A. 100% mucus severity score correlated with a raw score of 3.3, assessed as described in Materials and Methods. *, p<0.05; #, p>0.05. doi:10.1371/journal.pone.0063645.g003

Figure 3. R9-QQP specifically inhibits mucus production by goblet cells surrounding bronchioles. (A) Representative micrographs (200× magnification) of bronchioles prepared by staining (PAS) cross-sections of lung tissue of mice that had been treated as indicated in Figure 2A and detailed in Materials and Methods. Inset boxes display original image and red arrowheads indicate the presence of mucus producing goblet cells as defined by cytoplasms staining fuchsia. (B) Normalized averages (± SEM) of mucus severity scores for the indicated number (n) of mice calculated as described in Materials and Methods; for each mouse, approximately 30 bronchioles were stained and analyzed as in panel A. 100% mucus severity score correlated with a raw score of 3.3, assessed as described in Materials and Methods. *, p<0.05; #, p>0.05. doi:10.1371/journal.pone.0063645.g003
calculated the total numbers of eosinophils for multiple experiments using the indicated numbers of mice (Figure 5B). Compared to non-peptide treated animals (PC bar), R9-QQP treatment resulted in a 73% decrease in total eosinophils (Figure 5B). This significant reduction ($p < 0.05$) was peptide specific, as it was not seen when mice were treated with the control peptide R9-QQA (Figure 5B). Furthermore, the same effect on eosinophilia was observed when cells isolated from lung tissue were analyzed with the same markers as above (data not shown). In contrast, the total numbers of alveolar macrophages were not affected upon R9-QQP treatment (Figure 5C). Using a similar multicolor FACS-based approach, the percentage of T cells was measured from BAL cells that were stained for expression of CD45 and the TCR/CD3e (Figure 5D). The effect of R9-QQP treatment on infiltrating T cells mirrored that of eosinophils. That is, enumeration of total T cell numbers in BAL fluids showed a reduction of 63% upon R9-QQP treatment that was significant at $p < 0.05$ (Figure 5E). This effect was specific for R9-QQP, as treatment with the control...
peptide R9-QQA had no significant effect on T cell infiltration (Figure 5E).

R9-QQP treatment inhibits Th2 cytokine production by lymphoid cells from lung-draining lymph nodes

T lymphocytes that are recruited to the lungs in response to OVA stimulation and challenge (Figure 5D and E) secrete Th2 cytokines such as IL-4, IL-5, and IL-13 (Figure 6). Among other events, sustained levels of these cytokines are known to induce eosinophilia, goblet cell hyperactivity and mucus production [16,17]. Since ITK is known to regulate the transcriptional activation and secretion of Th2 cytokines [2,3], we tested the effects of R9-QQP treatment on the ability of antigen-specific T cells from OVA stimulated and challenged mice to produce IL-4, IL-5 and IL-13. Due to the limited numbers of T cells recruited to the inflamed lung tissue, we isolated T cells from the lung draining lymph nodes (DLN). Isolated lymphocytes from the peribronchial and mediastinal DLN of OVA-sensitized and control mice that had been treated with R9-QQP, no peptide, or R9-QQA control peptide were re-stimulated in vitro with OVA, but without

Figure 5. R9-QQP specifically inhibits eosinophilia. (A) Representative flow cytometric density plots obtained by specific antibody staining of BAL fluid cells from mice treated as indicated in Figure 2A and detailed in Materials and Methods. Inset box at bottom of graph outlines staining and analysis strategy: CD45+ cells gated and analyzed for Siglec-F and CD11c expression as described in Materials and Methods. Gates depict eosinophils and macrophages as percentages of total CD45+ cells. (B,C) Average (± SEM) number of eosinophils and macrophages respectively, calculated as described in Materials and Methods for the indicated number (n) of mice that had been treated as in panel (A). (D) Separate aliquots of BAL fluid cells from the experiment depicted in panel (A) analyzed as indicated in the inset box at the bottom of the graph: CD45+ cells gated by scatter and analyzed for CD3+ cells as described in Materials and Methods. Gates depict T lymphocytes as percentage of total CD45+ cells. (E) Average (± SEM) number of T cells calculated as described in Materials and Methods for the indicated number (n) of mice that had been treated as in panel (D). Axes in all histograms are displayed on a log scale for all fluorescence channels and on a linear scale for FSC. **, p < 0.0001; #, p>0.05; *, p<0.005.

doi:10.1371/journal.pone.0063645.g005
additional peptide treatment. The results in Figure 6 demonstrate that all three Th2 cytokines were significantly reduced in cultures prepared from the DLN of mice that were treated with R9-QQP but not those from the DLN of mice that were treated with control peptide or no treatment. Reduction was 85% in the case of IL-13 (Figure 6A), 71% for IL-5 (Figure 6B) and 73% for IL-4 (Figure 6C).

**Discussion**

The Inducible T cell kinase (ITK) is a major regulator of Th2 cytokine production and mice deficient in ITK (ITK-KO) fail to express Th2 effector function upon activation in the absence of cytokine receptor-mediated signaling [2,4,18]. The TCR-induced activation of ITK requires the interaction of the kinase with the adaptor protein SLP-76 [11,10,13]. Previous studies utilizing in vitro experimental systems or mice expressing mutated genes of SLP-76 have shown that the TCR-induced association between ITK and SLP-76 is co-operative, involving specific interactions between the ITK-SH2 domain and pTyr145 on SLP-76, as well as the interaction between the ITK-SH3 domain and its polyproline ligand on SLP-76 [9,10,13]. Jordan et al, utilizing mice bearing a mutation on tyrosine 145 (Y145F) of SLP-76, found that even though the TCR-induced association of ITK with SLP-76 was not perturbed, the activation of ITK was significantly compromised [10]. In our previous ex vivo studies, we demonstrated that the synthetic peptide R9-QQP, a specific competitive inhibitor of the ITK-SH3/SLP-76 poly-proline interaction, disrupted both the association between these two signaling partners, as well as the activation of ITK and subsequent Th2 cytokine production [12].

In these studies the R9-QQP mediated inhibition was specific for ITK, as other signaling partners such as LCK and ZAP-70 were not affected. These observations are consistent with the hypothesis that the interaction between ITK-SH3 and the poly-proline region of SLP-76 is a prerequisite for the interaction of the ITK-SH2 domain and Tyr-145 of SLP-76 and for the trans-phosphorylation and activation of ITK [12].

To further substantiate the above hypothesis, we have assessed the significance of the interaction between the SH3 domain of ITK and the poly-proline region of SLP-76 during an in vivo immune response as represented by lung inflammation in a murine model of allergic asthma. We found that treatment of mice with R9-QQP causes significant inhibition of the inflammatory immune response as manifested by airway hyper-responsiveness, inflammatory cell infiltration, bronchial mucus accumulation, and production of relevant cytokines from draining lymph nodes. The observed inhibition of these parameters is R9-QQP peptide specific because cell-permeable control peptides with scrambled amino acid sequence (R9-PQM) or peptides with substitutions of the critical proline residues with alanine (R9-QQA) lacked any significant effect. As it has been previously demonstrated, R9-QQP targets and disrupts the interaction between the SH3 domain of ITK and the poly-proline region of SLP-76 [12]. Although SLP-76 can interact with other SH3 domain-containing intracellular partners, R9-QQP specifically interferes with the interaction of the ITK-SH3 domain and the poly-proline region of SLP-76, as evidenced by the fact that the association between SLP-76 and LCK, and SLP-76 and GADS are not affected by R9-QQP [12]. The possibility that R9-QQP may not specifically

---

**Figure 6. R9-QQP inhibits a lung DLN Th2 cytokine response.** Cytokine levels of (A) IL-13, (B) IL-5, and (C) IL-4 in cultures of OVA (50 μg/ml) or medium restimulated lung-draining lymph node cells obtained from mice treated as described in Figure 2A and indicated in the inset legend. One ×10^5 (panels A and B) or 10^6 (panel C) cells per well of round-bottom 96-well microtiter trays were incubated for 4 days at 37°C and cell-free culture supernatants were assayed by ELISA as described in Materials and Methods. Results are displayed as the average (±SEM) cytokine amounts for the indicated number (N) of independent experiments each representing DLN cells pooled from 2-4 mice. **p < 0.01; #, p > 0.05; *, p < 0.05. doi:10.1371/journal.pone.0063645.g006
lymphocytes. It is known that the recruitment of eosinophils to the large influx of inflammatory cells into the lungs of allergic animals. It is known that the recruitment of eosinophils into local sites of inflammation involves several cytokines, most notably the Th2 cytokines IL-4, IL-5, and IL-13 that are produced by CD4+ T lymphocytes [20]. Therefore, it was not surprising to find that R9-QQP treatment significantly reduced recruitment of T cells to the lungs of allergic mice (Figure 5D and E).

Previous observations have suggested that ITK deficiency results in the inability to produce Th2 cytokines in antigen recall responses [2,21]. Consistent with this known role of ITK, it is interesting to note that a Th2 cytokine recall response by splenocytes from OVA-immune mice was significantly reduced upon treatment with R9-QQP in vitro (Figure 1). Furthermore, re-stimulation of lymphoid cells from lung draining lymph nodes of R9-QQP-treated, OVA-asthmatic mice also displayed reduced Th2 cytokine responses upon in vitro re-stimulation (Figure 6). Thus, similar to the situation in which ITK is genetically ablated (ITK-KO), blocking the TCR-inducible activation of ITK by inhibition of ITK; this possibility is consistent with a previously described role of ITK in the proliferation of OVA-specific CD4+ T cells clones during sensitization. Separately, our observations include a necessary role for ITK in the proliferation of OVA-specific CD4+ T cells clones during sensitization. Separately, our experiments (data not shown), we observed that OVA sensitization and challenge induced an increase in the levels of total serum IgE, however, treatment with R9-QQP had no effect on IgE levels unlike the reduction observed for parameters of lung inflammation. One interpretation that could account for these results could be that inhibition of ITK by R9-QQP may result in sufficient reduction of sustained levels of Th2 cytokines to alleviate the symptoms at the local site of inflammation occurring in the lung tissue, but not sufficient to inhibit T-cell-dependent isotype switching to IgE occurring in the B cell germinal center microenvironment of the lung draining lymph nodes. This interpretation is consistent with the data of Mueller and August who used a similar animal model to ours and observed that levels of OVA-specific serum IgE obtained from ITK-deficient mice were not significantly affected as compared to WT mice despite of reduced lung inflammation in the ITK-KO mice [5]. Finally, this interpretation is also consistent with other data in which increased IgE levels and mast cells did not always accompany lung inflammation in animal models such as the one utilized in the current study [26].

Other investigators have previously used chimeric peptides containing poly-arginine cationic domains for the intracellular delivery of inhibitory cargos. A notable example is the inhibition of the inducible nuclear translocation of NFAT, its transcriptional activity, and IL-2 production through the delivery of a specific peptide able to inhibit the interaction between calcineurin and NFAT [27]. This inhibitory peptide was conjugated to eleven arginine residues and, upon intraperitoneal injection, was able to prolong mismatched pancreatic islet allografts in mice in a transplant rejection model [27]. Another example is the inhibition of phosphorylation of cAMP responsive element-binding protein and long-term neuronal potentiation by a PKA inhibitory peptide that was delivered to the nuclei of neurons by a fusion peptide containing eleven arginines [28]. In addition, topical application of a conjugate of heptameric arginine and cyclosporine A successfully treated cutaneous inflammation in a murine model of contact dermatitis [29].

In conclusion, the present findings are significant in that 1) they provide the first demonstration of the biological importance of the SH3 domain-mediated interaction between ITK and SLP-76 in the activation of ITK and the subsequent Th2 cytokine production in a disease model, 2) they underscore the potential of cell permeable peptides as useful research tools for investigating signaling pathways in disease models, and 3) they provide translational implications for targeting ITK in the design of potential novel molecular therapies.

**Acknowledgments**

The authors would like to acknowledge the assistance of Brett Hilton (Dept. of Biology, San Diego State University) with Flow Cytometry and thank Ralph Feuer (Dept. of Biology, San Diego State University) for microscopy and Marilyn Thomas (Donahue-Shiley Bioscience Center, San Diego State University) for the use of anesthesia machine.

**Author Contributions**

Conceived and designed the experiments: DMG WD JDL MC CDT. Performed the experiments: DMG NRC NH. Analyzed the data: DMG WD JDL MC CDT. Contributed reagents/materials/analysis tools: WD JDL MC. Wrote the paper: DMG CDT.
References


